This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Spanish Network of Health Technology Assessment Agencies | |
|---|---|
| Name | Spanish Network of Health Technology Assessment Agencies |
| Native name | Red Española de Agencias de Evaluación de Tecnologías Sanitarias |
| Formation | 1980s–1990s (formalised 2003) |
| Headquarters | Madrid, Spain |
| Region served | Spain |
Spanish Network of Health Technology Assessment Agencies is a collaborative consortium of public and regional health assessment bodies in Spain that coordinates evaluation of medical devices, pharmaceuticals, and health services across autonomous communities. The Network operates at the interface of national Ministry of Health (Spain), regional health ministrys such as those of Catalonia, Community of Madrid, and Andalusia, and academic centres including university hospitals and research institutes. It serves as a forum for methodological harmonisation, joint reports, and dissemination to stakeholders such as the Spanish Agency of Medicines and Medical Devices, European European Medicines Agency, and international bodies.
The Network traces roots to early regional initiatives in the 1980s and 1990s when institutions in Basque Country, Navarre, and Valencian Community established independent assessment units. Formalisation occurred in the early 2000s amid policy reforms led by the Ministry of Health (Spain) and influenced by models from United Kingdom National Institute for Health and Care Excellence, Agence nationale d’évaluation des dispositifs médicaux and European initiatives such as the EUnetHTA. Major milestones include establishment of common governance protocols following deliberations at meetings involving the Spanish Society of Primary Care Physicians, Spanish Society of Hospital Pharmacists, and regional health agencies, and subsequent integration of university-linked centres like those at University of Barcelona and Autonomous University of Madrid.
The Network comprises member agencies from autonomous communities (e.g., Catalonia Health Service, Andalusian Health Service), national agencies including the Spanish Agency of Medicines and Medical Devices, and academic evaluation centres linked to universities and tertiary hospitals such as Hospital Universitario La Paz and Hospital Clínic de Barcelona. Governance typically involves a coordinating committee with representatives from regional ministries, a scientific secretariat drawn from academic groups, and working groups on therapeutics, diagnostics, and economics. Membership criteria mirror frameworks used by European Medicines Agency collaborations and reflect accreditation patterns similar to International Network of Agencies for Health Technology Assessment. Funding is mixed, combining regional budgets from entities like the Government of Spain and grants tied to programmes overseen by the Interterritorial Council of the National Health System.
Primary activities include production of health technology assessment (HTA) reports on oncology drugs, cardiology interventions, and medical imaging technologies; development of rapid reviews for policy-makers in regional parliaments; and training for clinicians from institutions such as Hospital Gregorio Marañón and La Fe University Hospital. The Network offers systematic reviews, cost-effectiveness analyses used by procurement bodies like municipal health services in Valencia, and horizon scanning aligned with European Horizon 2020 objectives. It convenes stakeholder consultations involving patient groups, professional societies such as the Spanish Society of Cardiology, and payers from regional health services.
Methodological workstreams harmonise approaches to evidence appraisal, economic modelling, and incorporation of real-world data from registries such as those maintained by university hospitals. Standards draw on guidance from Cochrane Collaboration, GRADE Working Group, and international HTA agencies including IQWiG and Canadian Agency for Drugs and Technologies in Health. The Network issues templates for systematic review protocols, quality assessment checklists, and transparency rules for conflict of interest management modeled after norms used by the World Health Organization and the European Commission. Training modules reference statistical methods taught at universities like University of Zaragoza and Complutense University of Madrid.
The Network actively engages with European initiatives including EUnetHTA, bilateral collaborations with agencies such as Haute Autorité de Santé and NHS England, and research partnerships with centres like Karolinska Institutet and Imperial College London. It works with industry stakeholders—pharmaceutical companies headquartered in Madrid or multinational firms—to facilitate evidence submission, while maintaining engagement with patient organisations and professional societies including the Spanish Society of Medical Oncology. Collaborative projects have included cross-border HTA pilots co-funded under EU programmes and joint assessments submitted to the European Medicines Agency.
Assessments by the Network have informed regional reimbursement decisions for high-cost treatments in oncology and rare diseases, and guided procurement of medical devices in tertiary hospitals such as Hospital Universitario 12 de Octubre. Evaluations attribute improved consistency in decision-making across autonomous communities and greater alignment with European HTA practices, as reflected in citations by policy reports and uptake by regional health technology procurement units. Independent audits and programme evaluations involving academic partners at University of Barcelona have documented efficiencies in report production and incremental cost savings from coordinated purchasing.
Challenges include balancing regional autonomy with standardisation across autonomous communities, integration of rapidly evolving evidence for personalised medicine, and managing conflicts of interest amid collaborations with multinational pharmaceutical firms. Future directions emphasize stronger engagement with EU-wide HTA regulation, expansion of real-world evidence platforms linked to hospital registries, and adoption of advanced health economic modelling techniques taught at research institutions like Universitat Pompeu Fabra and Barcelona Institute for Global Health. The Network aims to enhance transparency, broaden stakeholder inclusion, and increase interoperability with European and global HTA frameworks.
Category:Health technology assessment Category:Healthcare in Spain